NCT01271972View on ClinicalTrials.gov

Study of Nesvacumab (REGN910/ SAR307746)

PHASE1CompletedINTERVENTIONAL

Enrollment

53

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

May 31, 2015

Conditions

Solid Tumors

Interventions

DRUG

nesvacumab (REGN910/ SAR307746)

Trial Locations (3)

Unknown

San Francisco

San Antonio

Toronto

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY